Bambu Ventures plans to bid $10 million for 23andMe’s online health-care platform as the DNA testing firm seeks court approval to sell its assets to its cofounder and a nonprofit.

RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with ...

By the end of the next 10 years, the UK’s National Health Service (NHS) is aiming to test the DNA of every baby born, as part ...

Oxford City Council has said it fell victim to a security breach over the weekend of 7–8 June, which may have compromised ...

Attorney General Gentner Drummond has filed a federal lawsuit to block genetic testing company 23andMe from selling the private DNA information of 15 million customers without their permission. He ...

UBS has decided Regeneron Pharmaceuticals needs a new wardrobe, trimming its price target from $633 to a more modest $560.

Power chip biz to hand over equity to lenders, wipe out most shareholders, and keep running during restructuring Wolfspeed, ...